1Senning A. Alterations in valvular surgery: biologic valve. In.. CohnL H, Gallucci V, editors. Cardiac bioprostheses: proceedings of thesecond international symposium on cardiac bioprostheses. New York:Yorke Medical Books, 1982. 140-153.
2Hetzer R, Topalidis T, Borst H. Thromboembolism andanticoagulation after isolated mitral valve replacement withporelne heterografts. In: Cohn LH, Gallucci V, eds.Proceedings, Second International Symposium Cardiac Bioprostheses. New York: Yorke Medical Books, 1982. 170-172.
2Landefeld CS,Goldman L. Major bleeding in outpatients treated with warfarin:incidence and prediction by factors known at the start of outpatient therapy. Am J Med, 1989,87(2) : 144-152.
3Turner-Gomes SO, Mitchell L, Williams WG,et al. Thrombin regulation in congenital heart disease after cardiopulmonary bypass operations. J Thorac Cardiovasc Surg, 1994,107(2):562-568.
4Ageno W, Turpie AG, Steidl L, et al. Comparison of a daily fixed 2.5mg warfarin dose with a 5mg international normalized ratio adjusted, warfarin dose initially following heart valve replacement. Am J Cardiol,2001,88(1 ):40-44.
6Ananthasubramaniam K, Beattie JN, Rosman HS.et al.How safely and for how long can warfarin therapy be withheld in prosthetic heart valve patients hospitalized with a major hemorrhage,Chest,2001,119(2):487-484.
7Wijdicks EF, Schievink Wl, Brown RD, et al. The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves.Neurosurgery, 1998,42(4) :769-773.
1Hetzer R,Topalidis T,Borst H.Thromboembolism and anticoagulation after isolated mitral valve replacement with porcine heterografts.In:Cohn LH,Gallucci V,eds.Proceedings,Second International Symposium on Cardiac Bioprostheses.New York:Yorke Medical Books,1982.170-172.
